Everett E. Vokes to Protein Kinase Inhibitors
This is a "connection" page, showing publications Everett E. Vokes has written about Protein Kinase Inhibitors.
Connection Strength
2.846
-
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study. Cancer. 2020 07 15; 126(14):3237-3243.
Score: 0.543
-
Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains? J Clin Oncol. 2019 11 01; 37(31):2807-2814.
Score: 0.519
-
The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist. 2009 Nov; 14(11):1116-30.
Score: 0.262
-
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2009 Oct; 45(10):e155-60.
Score: 0.257
-
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
Score: 0.242
-
ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. Clin Cancer Res. 2015 Dec 15; 21(24):5439-44.
Score: 0.100
-
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. PLoS One. 2013; 8(7):e67668.
Score: 0.085
-
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012 Oct; 78(1):76-80.
Score: 0.079
-
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report. J Thorac Oncol. 2012 Apr; 7(4):755-9.
Score: 0.078
-
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer. 2012 Jun; 76(3):393-6.
Score: 0.076
-
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012 Jun; 30(3):1211-5.
Score: 0.073
-
Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context. Mol Cancer Ther. 2010 Oct; 9(10):2814-24.
Score: 0.070
-
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol. 2010 Nov 01; 28(31):4740-6.
Score: 0.070
-
A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). J Thorac Oncol. 2010 Mar; 5(3):380-4.
Score: 0.067
-
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 01; 69(7):3021-31.
Score: 0.063
-
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 01; 26(7):1119-27.
Score: 0.058
-
Angiogenesis inhibition in the treatment of lung cancer. Clin Adv Hematol Oncol. 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2.
Score: 0.053
-
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res. 2005 Nov 15; 11(22):8105-8.
Score: 0.050
-
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 02 10; 41(5):1105-1115.
Score: 0.040
-
Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. Sci Rep. 2017 08 23; 7(1):9192.
Score: 0.028
-
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011 Jul 01; 12(1):9-46.
Score: 0.018
-
Protein kinase C beta in malignant pleural mesothelioma. Anticancer Drugs. 2008 Oct; 19(9):841-8.
Score: 0.015